May 18, 2020 / 12:55 PM / 14 days ago

BRIEF-Neurotrope, Metuchen Pharma Report Merger Agreement

May 18 (Reuters) - Neurotrope Inc:

* NEUROTROPE AND METUCHEN PHARMACEUTICALS ANNOUNCE MERGER AGREEMENT TO FORM PETROS PHARMACEUTICALS, A MEN’S HEALTH COMPANY

* NEUROTROPE INC - DEAL FOR ALL-STOCK TRANSACTION

* NEUROTROPE INC - EXISTING NEUROTROPE SHAREHOLDERS WILL OWN APPROXIMATELY 20% AND METUCHEN SHAREHOLDERS WILL OWN APPROXIMATELY 80% OF COMBINED COMPANY

* NEUROTROPE INC - CHARLES RYAN NAMED PRESIDENT AND CHIEF EXECUTIVE OFFICER OF PETROS

* NEUROTROPE - FUNDING FOR PETROS EXPECTED TO INCLUDE ABOUT $20 MILLION OF CO’S AVAILABLE CASH AND CASH EQUIVALENTS, REVENUE FROM SALES OF METUCHEN’S STENDRA

* NEUROTROPE INC - PETROS IS EXPECTED TO BECOME A NASDAQ TRADED COMPANY FOCUSED SOLELY ON MEN’S HEALTH CONDITIONS

* NEUROTROPE - BRYOSTATIN-1 AND ALL EXISTING ASSETS, OPERATIONS AND LIABILITIES, EXCEPT FOR CASH RETAINED BY PETROS WILL BE SPUN-OUT INTO A SEPARATELY TRADED CO

* NEUROTROPE INC - NEUROTROPE BIOSCIENCE EXPECTED TO RETAIN ABOUT $14 MILLION WHICH INCLUDES CASH PLUS RECENTLY AWARDED NIH CLINICAL TRIAL GRANT

* NEUROTROPE INC - STAKEHOLDERS OF NEUROTROPE PRIOR TO MERGER WILL OWN ALL OF SHARES OF NBI Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below